Title of Invention	PROCESS FOR PREPARATION OF AMORPHOUS HMG-CoA REDUCTASE INHIBITOR AND HYDRATES
Abstract	A process for the preparation of amorphous HMG-CoA reductase inhibitor and its hydrates thereof of desired particle size, which comprises: (a) dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent; (b) removing the solvent by freeze-drying.

Full Text

FIELD OF THE INVENTION: The present invention relates to a process for the production of amorphous HMG"CoA reductase inhibitors of desired particle size. BACKGROUND OF THE INVENTION: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin and cervastatin and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products. The present invention relates to amorphous form HMG-CoA reductase inhibitors, which are useful as a pharmaceutical to substance, to the method for its production and isolation HMG-CoA reductase inhibitors, which are used for the treatment of hyperlipidemia and hypercholesterolemia, both of which are risk factors for arteriosclerosis and coronary heart disease. United States Patent 5,273,995, describes that R-form of as the ring opened acid form inhibits the biosynthesis of cholesterol. Atorvastatin in its calcium salt form, i.e. amorphous [R-(R*, R*)-]2-(4-fluorophenyl)-p, 5-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (2: I) is discussed in literature. Various United States patents like, 5,003,080; 5,097,045; 5,103,024; 5,124,482; 5,149,837; 5,248,793; 5,280,126; 5,342,952, which are herein incorporated by reference, describe various processes and key intermediates for preparing atorvastatin calcium. The process mentioned in the above patents does not produce atorvastatin calcium in its amorphous form consistently. Often a mixture of crystalline and amorphous form is obtained which is not suitable for filtration and drying and therefore not a desirable process for large-scale production. PCT application, WO 97/03959, discloses novel crystalline forms of atorvastatin calcium designated as Form I, Form II, and Form IV and method for their preparation. PCT application WO 97/03960 describes a procedure for converting the crystalline form of atorvastatin to the amorphous form. The process described in the above mentioned patent to involves dissolving the crystalline atorvastatin (form-l) in a non hydroxylic solvent like tetrahydrofuran or mixtures of tetrahydrofuran and toluene, followed by removal of the solvents under high temperature (about 90°C) and high vacuum (about 5mm). This process may not suitable on a large scale as the conditions used for drying may lead to degradation of the product. PCT application WO 00/71116 claims a process for the preparation of amorphous atorvastatin calcium v/here the crystalline form is dissolved in a non-hydroxilic solvent is treated with a non-polar hydrocarbon anti- solvent followed by the removal of the solvent to result in the amorphous form. Pravastatin, which was first reported as a metabolite of compactin in US 4,346,227. W001/43723 describes certain novel forms of pravastatin, which are characterized by X-Ray patterns. SUMMARY OF THE INVENTION: It is desirable to have a process, which provides amorphous HMG- CoA reductase inhibitor using a procedure, which can be readily scaled up to a commercial scale. The present invention describes a process, which is ideal for large-scale production of amorphous HMG- CoA reductase inhibitor. The present invention provides a process for the preparation of amorphous HMG-CoA reductase inhibitor and hydrates thereof of desired particle size, which comprises: (i) dissolving the heterogeneous mixture of HMG- CoA reductase inhibitor in a hydroxylic solvent and (ii) removing the solvent to obtain amorphous HMG-CoA reductase inhibitor. The process further comprises: (iii) subjecting the amorphous HMG- CoA reductase inhibitor to milling. The solvent is removed by freeze drying or spray drying. The amorphous HMG-CoA reductase inhibitor has a particle size of to 150 microns. The hydroxylic solvent solvent in step (i) is methanol. The HMG-CoA reductase inhibitor is a statin, preferably, atorvastatin or pravastatin having a particle size of to 150 microns. Major advantages of the present invention compared to the prior art processes are: i. Produces amorphous HMG-CoA reductase inhibitor consistently, ii. Results in the final product of desired particle size, iii. Avoids the necessity to remove solvents, iv. Simpler and faster filtration. V. Easy to operate on large-scale, vi. Avoids the use of hydrocarbons. The present invention thus provides a simple and novel process for the preparation of amorphous atorvastatin calcium and hydrates thereof. The starting material used in the instant invention comprises of a mixture of both amorphous and crystalline forms- henceforth referred to as heterogeneous mixture. BRIEF DESCRIPTION OF THE ACCOMPANYING FIGURES: Figure 1 is the diffractogram of amorphous atorvastatin calcium. The horizontal axis represents 29 and the vertical axis corresponds to peak intensity. Figure 2 is the diffractogram of amorphous pravastatin. The horizontal axis represents 20 and the vertical axis corresponds to peak intensity. The present invention is illustrated by the following examples, which an intended to limit the effective scope of the claims. DETAILED DESCRIPTION OF THE INVENTION: Major advantages of the present invention compared to the prior art processes are: i. Produces amorphous HMG-CoA reductase inhibitor consistently, ii. Results in thefinal product of desired particle size. 'v iii. Avoids the necessity to remove solvents, iv. Simpler and faster filtration. V. Easy to operate on large-scale, vi. Avoids the use of hydrocarbons. The present invention thus provides a simple and novel process for the preparation of amorphous atorvastatin calcium I, and hydrates thereof. The starting material used in the instant invention comprises of a mixture of both amorphous and crystalline forms - henceforth referred to as heterogeneous mixture. The present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. EXAMPLES: Example 1: [R-(R*,R*)]-2-(4-fluorophenyl)-,6,5-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(pheny[amino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Amorphous Atorvasatin calcium). A heterogenous mixture of atorvastatin (5g) was added to methanol (100ml) and the resulting reaction mixture was freeze dried to afford amorphous atorvastatin. The particle size as measured by malvern particle size analyser gave the following pattern: D10 3 microns D50 9 microns D90 16 microns Example 2: [1S-([1a(6*,6*)2a,6a,8B(R*),8aa]]-1,2,6,7,8, 8a-hexahydro- B,a,6- trihydroxy-2-methyl-8-(2-methyl-1-oxabutoxy)-1-naphthalene heptanoic acid sodium salt (Amorphous Pravastatin) A heterogenous mixture of pravastatin sodium (5g) was added to methanol (100ml) and the resulting reaction mixture was spray dried to afford amorphous pravastatin sodium. The amorphous pravastatin sodium so obtained was milled using an air jet mill. The particle size as measured by malvern particle size analyser gave the following pattern: D10 3 microns D50 11 microns D90 19 microns Example 3: [1S-([1a(B*,6*)2a,6a,8B(R*),8aa]]-1,2,6,7,8,8a-hexahydro-,B,5,6-trihydroxy-2-methyl-8-(2-methyl-1-oxabutoxy)-1-naphthalene heptanoic acid sodium salt (Amorphous Pravastatin) A heterogenous mixture of pravastatin sodium (59) was added to water (100ml) and the resulting reaction mixture was spray dried to afford amorphous pravastatin sodium. The amorphous pravastatin sodium so obtained was milled using an air jet mill. The particle size as measured by malvern particle size analyser gave the following pattern: Dio 2 microns D50 4 microns D90 10 microns Example - 4: [R-(R*,R*)]-2-(4-fluorophenyl)-B,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Amorphous Atorvasatin calcium). A heterogenous mixture of atorvastatin (5g) was added to methanol (tOOml) and the resulting reaction mixture was spray dried to afford amorphous atorvastatin. The particle size as measured by malvern particle size analyser gave the following pattern: D10 1 microns D50 6 microns D90 11 microns Example 5: [1S-([1a(6*,5*)2a,6a,8B(R*),8aα]]-1,2,6,7,8,8a-hexahydro-B,6,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthalene heptanoic add sodium salt (Amorphous Pravastatin) A heterogenous mixture of pravastatin sodium (5g) was added to methanol (100ml) and the resulting reaction mixture was freeze dried to afford amorphous pravastatin sodium. The amorphous pravastatin sodium so obtained was milled using an air jet mill. The particle size as measured by malvern particle size analyser gave the following pattern: Dio 2 microns D50 8 microns D90 16 microns X-ray powder diffraction pattern (Figure 1 and 2 as shown in the accompanied drawings) demonstrates the amorphous nature of the product. We claim: 1. A process for the preparation of amorphous HMG-CoA reductase inhibitor and hydrates thereof of desired particle size, which comprises: (i) dissolving the heterogeneous mixture of HMG-CoA reductase inhibitor In a hydroxylic solvent and (ii) removing the solvent to obtain amorphous HMG-CoA reductase inhibitor by freeze drying. 2. The process of claim 1, further comprising (iii) subjecting the amorphous HMG-CoA reductase inhibitor to milling. 3. The process of claim 1 wherein the solvent is removed by spray drying instead of freeze drying. 4. The process of claim 1, wherein the amorphous HMG-CoA reductase inhibitor has a particle size of 1 to 150 microns. 5. The process of claim 1, wherein the hydroxylic solvent in step (i) is methanol. 6. The process of claim 1, vvherein the HMG-CoA reductase inhibitor is a statin. 7. The process of claim 6, wherein the HMG-CoA reductase inhibitor is atorvastatin or pravastatin. 8. The. process of claim 6, wherein Atorvastatin is Atorvastain calcium amorphous of particle size 1 to 150 microns. 9. The process of claim 6, wherein Pravastatin is Pravastatin calcium amorphous of particle size 1 to 150.

Documents:

2063-chenp-2004-abstract.pdf

2063-chenp-2004-claims filed.pdf

2063-chenp-2004-claims granted.pdf

2063-chenp-2004-correspondnece-others.pdf

2063-chenp-2004-correspondnece-po.pdf

2063-chenp-2004-description(complete)filed.pdf

2063-chenp-2004-description(complete)granted.pdf

2063-chenp-2004-drawings.pdf

2063-chenp-2004-form 1.pdf

2063-chenp-2004-form 19.pdf

2063-chenp-2004-form 26.pdf

2063-chenp-2004-form 3.pdf

2063-chenp-2004-form 5.pdf

2063-chenp-2004-pct.pdf